.jetcityimage/iStock Content by means of Getty Images Morgan Stanley has actually opted for Eli Lilly (NYSE: LLY) as its best biopharma pick for 2025 and ranked yet another nine titles in the area as obese. The assets banking company pointed out in a keep in mind that it remains to think “diabesity is set to become.